Biogen Inc. Announces Q1 2025 Financial Results

Biogen Inc. has kicked off its fiscal year 2025 with a notable 6% increase in total revenue, reaching $2.4 billion in the first quarter, as disclosed in a recent press release. This growth is compared to the same period in 2024, showcasing the company's resilience and strategic focus.

Financial Performance Highlights

Despite the revenue uptick, the company faced challenges with GAAP diluted earnings per share, which decreased year over year to $1.64. Additionally, net income attributable to Biogen Inc. for the quarter ending March 31 was reported at $240.5 million.

Leadership's Perspective on Growth

"Biogen delivered strong first-quarter results, supporting our strategy for long-term growth. We are particularly encouraged by the transformation in our commercial product portfolio, with approximately 45% of total product revenue in the first quarter coming from important medicines outside of our MS business," stated CEO Christopher Viehbacher, highlighting the company's diversified success.